NAICS Code: 325412

Period of Performance: 04/01/2013 to 03/31/2014

Contract Award Dollar Amount: $18,284,160

Contract Line Item Number: 0005

Award Date: 09/13/13

The statutory authority permitting other than full and open competition is 41 U.S.C. 253(c)(1) as cited in FAR 13.106-1(b)(1)(i). It is critical to ensure that sufficient doses of PRP-OMP Hib-containing vaccines, which are only produced by one licensed manufacturer in the US and which are preferred for use in high risk children, including American Indian/Alaska Native (AI/AN) children, are available to fully protect children against invasive Hib disease. Not adding additional doses of these vaccines on Merck's contract will adversely impact CDC's ability to adequately protect pediatric patients, particularly high risk children such as American Indian/Alaska Native (AI/AN) children, against invasive Hib disease.

Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement, proposal or quotation which shall be considered by the agency for future procurement. Please forward the capability statement and/or pricing information to Michael Harwell, Contracting Specialist, Reference 200-2013-54509, Centers for Disease Control, Procurement and Grants Office, ATTN: Michael Harwell, MS: K14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov.

This is a posting of a sole source award to Merck Sharp & Dohme Corp. and is not a request for competition.